O
DYN icon

OrbiMed’s Dyne Therapeutics DYN Stock Holding History

OrbiMed’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$71.9M Buy
3,235,684
+317,800
+11% +$5.91M 1.33% 19
2026
Q1 		$52.9M Buy
2,917,884
+715,700
+32% +$12.3M 1.05% 29
2025
Q4 		$43.1M Sell
2,202,184
-112,000
-5% -$2.12M 0.88% 36
2025
Q3 		$29.3M Buy
2,314,184
+1,282,784
+124% +$14.6M 0.69% 43
2025
Q2 		$9.82M Buy
1,031,400
+16,789
+2% +$185K 0.25% 59
2025
Q1 		$10.6M Sell
1,014,611
-212,469
-17% -$3.04M 0.25% 60
2024
Q4 		$28.9M Buy
1,227,080
+518,680
+73% +$15.3M 0.59% 45
2024
Q3 		$25.4M Hold
708,400
– – 0.46% 55
2024
Q2 		$25M Hold
708,400
– – 0.49% 51
2024
Q1 		$20.1M Buy
+708,400
New +$16M 0.37% 64
2022
Q4 		– Sell
-220,400
Closed -$2.8M – 120
2022
Q3 		$2.8M Buy
+220,400
New +$2.53M 0.05% 117
2021
Q3 		– Sell
-350,000
Closed -$7.36M – 180
2021
Q2 		$7.36M Hold
350,000
– – 0.07% 139
2021
Q1 		$5.44M Hold
350,000
– – 0.05% 141
2020
Q4 		$7.35M Hold
350,000
– – 0.06% 133
2020
Q3 		$7.07M Buy
+350,000
New +$7.68M 0.09% 120

Other funds holding DYN

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

OrbiMed's DYN Position: Q2 2026 in Review

OrbiMed increased its Dyne Therapeutics (DYN) stake by 11% in Q2 2026, buying an estimated $5.91M and bringing the position to 3,235,684 shares worth $71.9M. The position accounts for 1.33% of the portfolio, ranked #19.

OrbiMed first reported a position in DYN in Q3 2020 and has held it in 15 quarters since. 246 funds tracked by Wall St. Rank hold DYN as of Q2 2026.

  • OrbiMed held 3,235,684 shares of Dyne Therapeutics worth $71.9M as of Q2 2026.
  • OrbiMed bought 317,800 Dyne Therapeutics shares in Q2 2026, an estimated $5.91M.
  • Dyne Therapeutics made up 1.33% of OrbiMed's portfolio in Q2 2026, its #19 holding.
  • OrbiMed first reported a position in Dyne Therapeutics in Q3 2020 and has held it in 15 quarters since.
  • 246 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q2 2026.

Based on OrbiMed's 13F filing for Q2 2026, filed 14 Aug 2026.